{"id":"W2792717752","doi":"10.1016/j.eururo.2018.03.006","title":"Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer","year":2018,"lang":"en","type":"article","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"ca_institutions":"Kingston Health Sciences Centre; Canadian Centre for Applied Research in Cancer Control; Queen's University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Medicine; Willingness to pay; Bladder cancer; Cost effectiveness; Cancer; Internal medicine; Oncology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002477687,0.0001583076,0.0003601682,0.000124643,0.00002620719,0.000002577138,0.0001019211,0.00005147882,0.001601828],"category_scores_gemma":[0.00005238215,0.0001359692,0.0000606348,0.0001850662,0.0002084273,0.00004354132,0.00005428833,0.0001625481,0.0001574834],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006200682,"about_ca_system_score_gemma":0.0001046922,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005666424,"about_ca_topic_score_gemma":0.0001531161,"domain_scores_codex":[0.9986616,0.0003815721,0.0002524494,0.0003214842,0.0001002451,0.0002826704],"domain_scores_gemma":[0.9993435,0.00008886067,0.00007665,0.0002910224,0.000115994,0.00008393359],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06822053,0.003712572,0.3367806,0.001120962,0.001867039,0.002277828,0.004597832,0.0004689484,0.2963464,0.001734086,0.004182488,0.2786907],"study_design_scores_gemma":[0.01725233,0.004555269,0.891931,0.00007830231,0.0001623345,0.0001086119,0.00003068532,0.00007657357,0.03506841,0.0001540627,0.0503679,0.0002145414],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9318085,0.0008212118,0.0001607993,0.0002333946,0.0004181168,0.0006439944,0.00003303033,0.00004208988,0.06583885],"genre_scores_gemma":[0.9975405,0.00006919399,0.00007042497,0.001180691,0.0002560558,0.00004677053,0.00001635225,0.00004716494,0.0007728716],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5551503,"threshold_uncertainty_score":0.9993109,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04143714961842677,"score_gpt":0.3442876869679283,"score_spread":0.3028505373495015,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}